Answers are grounded in this paper and cite their sources.
Introduction: Asthma is a chronic airway disease that has a substantial impact on increased health-care utilization, including a substantive impact on quality of life and morbidity. Biologics are considered in patients with severe asthma and who have poor baseline symptom control and recurrent exacerbations that require emergency department visits, hospitalizations, and prolonged steroids courses. With six different biologics currently being available to treat severe uncontrolled asthma, the choice of which biologic to proceed with is usually based on the biomarkers and clinical characteristics, including comorbidities. The lack of response in some patients suggests that there may be an interplay of more complex immunologic pathways that are contributing to the severity of asthma in said patients. In this review, we attempted to highlight what we know about the various biomarkers used in the management of asthma, while also shedding light on what is yet to be known and understood. We also briefly delved into the various clinical characteristics in patients with severe asthma that may influence the choice of one biologic over the other. Methods: An extensive PubMed search was conducted by using the search terms benralizumab, dupilumab, mepolizumab, and omalizumab. Additional search terms included asthma biomarkers, exhaled nitric oxide, blood and sputum eosinophil counts, total IgE levels, comorbidities, and predictors of response. In general, all searches dated back ∼10 years, with the exception of the omalizumab data. Discussion: Although there is no doubt that biomarkers have a role in the management and stratification of asthma, we must understand that there are several nuances to using them when evaluating a patient and when making decisions on the biologic of choice and subsequent monitoring of these patients. There are still substantial gaps in our knowledge of how they should be reliably used in asthma management, and it is important to understand the limitations to avoid overestimating the extent of their utility.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: